Full text is available at the source.
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus
Tirzepatide's effects on blood sugar control and weight loss compared to similar medicines in Japanese people with type 2 diabetes
AI simplified
Abstract
Tirzepatide 15 mg resulted in a significant reduction in HbA1c levels and body weight in Japanese patients with type 2 diabetes.
- 18 randomized controlled trials were analyzed for the comparison of GLP-1RAs and GIP/GLP-1RAs.
- Tirzepatide 15 mg reduced HbA1c levels more than subcutaneous semaglutide 1.0 mg (mean difference -0.52) and oral semaglutide 14 mg (mean difference -1.23).
- Tirzepatide also led to greater body weight reduction compared to subcutaneous semaglutide (-5.07 kg) and oral semaglutide (-6.84 kg).
- Subcutaneous semaglutide demonstrated superior HbA1c reduction compared to oral semaglutide.
- Both subcutaneous and oral semaglutide were more effective than conventional GLP-1RAs like dulaglutide, liraglutide, and lixisenatide.
AI simplified